Shigemi Ishikawa

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medication is the principle approach once this occurs. There(More)
  • 1